Form 4 Filing for Mineralys Therapeutics, Inc.

This filing details transactions by Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc. On April 17, 2026, Mr. Malcom acquired 416 shares of Common Stock at $15.44 per share and disposed of 416 shares of Common Stock at $31.33 per share, pursuant to a Rule 10b5-1 trading plan. Additionally, Mr. Malcom exercised a stock option for 416 shares of Common Stock at an exercise price of $15.44. Following these transactions, Mr. Malcom directly owns 69,792 shares of Common Stock and holds 4,584 vested stock options.